Oruka Therapeutics Inc ORKA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $104.68
- Day Range
- $104.59–109.42
- 52-Week Range
- $14.03–109.42
- Bid/Ask
- $43.18 / $125.00
- Shares Outstanding
- 66.21M
- Market Cap
- $7.11B
- Volume/Avg
- 20 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 68
- Website
- https://www.orukatx.com
Valuation
|
Metric
|
ORKA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.90 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ORKA
|
|---|---|
Quick Ratio | 38.03 |
Current Ratio | 38.51 |
Interest Coverage | — |
Quick Ratio
ORKA
Profitability
|
Metric
|
ORKA
|
|---|---|
Return on Assets (Normalized) | −17.40% |
Return on Equity (Normalized) | −18.06% |
Return on Invested Capital (Normalized) | −21.78% |
Return on Assets
ORKA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|T^^F!m | LOCK|%J<#Q | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|g@!^h$ | LOCK|f&Q> | $82B | |||
| argenx SE ADR
ARGX
| LOCK|%bBr#R> | LOCK|>$ | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|d@j%F?s | LOCK|$%dn | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|p<JrFVl | LOCK|wq | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ljt!$! | LOCK|vs?Lw | $30B | |||
| Moderna Inc
MRNA
| LOCK|s^D?R< | LOCK|NT | $25B | |||
| Incyte Corp
INCY
| LOCK|!!HX@$m | LOCK|%r< | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|Y^BHt# | LOCK|V^ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<x@X<dH | LOCK|wtr | $16B |
United States